These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 951835)

  • 1. Tin-protein binding kinetics in normal and uremic plasma and its effect on dialysis fluxes.
    Maher JF; Montero G; Chieffo S
    Trans Am Soc Artif Intern Organs; 1976; 22():149-54. PubMed ID: 951835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis.
    Asad SN; Olmer AJ; Letteri JM
    Miner Electrolyte Metab; 1984; 10(5):333-6. PubMed ID: 6493162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein binding of ceftriaxone: comparison of three techniques of determination and the effect of 2-hydroxybenzoylglycine, a drug-binding inhibitor in uremia.
    Fiset C; Vallée F; LeBel M; Bergeron MG
    Ther Drug Monit; 1986; 8(4):483-9. PubMed ID: 3824437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma protein binding of zolpidem in liver and renal insufficiency.
    Pacifici GM; Viani A; Rizzo G; Carrai M; Ganansia J; Bianchetti G; Morselli PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):439-43. PubMed ID: 3198298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uremic hyperstannum: elevated tissue tin levels associated with uremia.
    Nunnelley LL; Smythe WR; Alfrey AC; Ibels LS
    J Lab Clin Med; 1978 Jan; 91(1):72-5. PubMed ID: 618991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red blood cell calcium homeostasis in patients with end-stage renal disease.
    Gafter U; Malachi T; Barak H; Djaldetti M; Levi J
    J Lab Clin Med; 1989 Sep; 114(3):222-31. PubMed ID: 2527934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous accumulation products and serum protein binding in uremia.
    McNamara PJ; Lalka D; Gibaldi M
    J Lab Clin Med; 1981 Nov; 98(5):730-40. PubMed ID: 7299243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of plasma concentration determinations: phenytoin.
    Adler DS
    Clin Toxicol; 1979; 14(2):147-50. PubMed ID: 436388
    [No Abstract]   [Full Text] [Related]  

  • 11. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa.
    Thekkedath UR; Chirananthavat T; Leypoldt JK; Cheung AK; Mohammad SF
    Am J Hematol; 2006 Dec; 81(12):915-26. PubMed ID: 16917914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of uremia and hemodialysis on the plasma protein binding of tolmetin.
    Pritchard JF; O'Neill PJ; Affrime MB; Lowenthal DT
    Pharmacology; 1984; 29(6):312-9. PubMed ID: 6505005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of uremic plasma fractions of different molecular sizes on the filterability of red blood cells].
    Eggert W; Scigalla P; Noack C; Devaux S; Wolf S
    Z Urol Nephrol; 1981 May; 74(5):391-9. PubMed ID: 7269824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
    Lacour B; Di Giulio S; Nicolaï A; Drüeke T; Debray M; Boulu RG
    Nephrologie; 1982; 3(1):19-22. PubMed ID: 7088259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First evidence for accumulation of protein-bound and protein-free pyrraline in human uremic plasma by mass spectrometry.
    Odani H; Shinzato T; Matsumoto Y; Takai I; Nakai S; Miwa M; Iwayama N; Amano I; Maeda K
    Biochem Biophys Res Commun; 1996 Jul; 224(1):237-41. PubMed ID: 8694819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and determination of phenylacetylglutamine, a major nitrogenous metabolite in plasma of uremic patients.
    Zimmerman L; Egestad B; Jörnvall H; Bergström J
    Clin Nephrol; 1989 Sep; 32(3):124-8. PubMed ID: 2791363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis.
    Shahbazian H; Zand Moghadam A; Ehsanpour A; Khazaali M
    Iran J Kidney Dis; 2009 Jul; 3(3):151-5. PubMed ID: 19617664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K; Conway P; Shapiro R
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.